In Massachusetts, Hatfield previously also worked at Bristol-Myers Squibb (BMS). He earned an MBA from The Wharton School of the University of Pennsylvania and a Bachelor’s degree in pharmacy from Purdue University. He isn’t new to Board memberships, having served or currently serving on Boards for Ambit Biosciences and Biotechnology Industry Organization (BIO). Invivo focuses on treatment of spinal cord injuries using biomaterials and biotechnology, which is a good fit for Hatfield who told The Atlantic “I’m personally very motivated and excited by the company’s work, as I’ve had direct experience with a family member who suffered a serious spinal cord injury at an early age,” Hatfield said. “I’m hopeful that Mark and the InVivo team can make a meaningful difference to the lives of those suffering these kinds of traumatic injury.”
Latest article
Spiderman, but kind of goth: University of Bayreuth team creates red silk-producing spiders
In Germany, researchers at the University of Bayreuth’s Biomaterials research group have used the CRISPR-Cas9 gene-editing technology to create spiders that produce red fluorescent...
BoilMate corn-fiber cooking bowl seeks funding on Kickstarter
In California, Transcarton has launched a Kickstarter campaign for BoilMate—the world’s first fire-safe, compostable paper bowl engineered for instant cooking.
BoilMate combines FDA-approved corn fiber...
Natural Indigo Finland, TAMK turn coffee waste into ink for packaging
In Finland, Natural Indigo Finland and Tampere University of Applied Sciences (TAMK) have developed a water-based ink using biocolorant extracted from coffee waste supplied...